|
 |
GemifloxacinThis page contains recent news articles, when available, and an overview of Gemifloxacin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Gemifloxacin (when available) Gemifloxacin is a quinolone/fluoroquinolone antibiotic. Gemifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Gemifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. For the treatment of Bacterial infection caused by susceptible strains such as S.pneumoniae, H.influenzae, H.parainfluenzae, or M.catarrhalis, S.pneumoniae (including multi-drug resistant strains [MDRSP]), M.pneumoniae, C.pneumoniae, or K.pneumoniae. Mechanism Of Action: The bactericidal action of Gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. News Articles on Gemifloxacin Antibiotic Therapy in Elderly Patients with Acute Exacerbation of Chronic ... - Dec 21, 2009 Wilson R, Langan C, Ball P, Bateman K, Pypstra R. Oral gemifloxacin once daily for 5 days compared with sequential therapy with iv ceftriaxone/oral ... Medscape Antibiotic Fails to Win Panel's Support - Sep 12, 2006 Studies have found serious skin reactions associated with use of the drug, also known as gemifloxacin. The FDA approved the drug in 2003 to treat pneumonia ... San Francisco Chronicle Gemifloxacin (Systemic). - Jul 28, 2005 Gemifloxacin (ji-mi-FLOX-a-sin) belongs to the class of medicines known as antibiotics. It is used to treat bronchitis and pneumonia caused by bacterial ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Gemifloxacin (Systemic).(Drug overview) - May 1, 2006 Gemifloxacin (ji-mi-FLOX-a-sin) belongs to the class of medicines known as antibiotics. It is used to treat bronchitis and pneumonia caused by bacterial ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com GEMIFLOXACIN (Oral route) - je-mi-FLOX-a-sin.(Drug overview) - May 1, 2007 Gemifloxacin belongs to the class of medicines known as antibiotics. It is used to treat bronchitis and pneumonia caused by bacterial infections. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Gemifloxacin voted down for sinusitis.(News) - Nov 1, 2006 GAITHERSBURG, MD. -- A Food and Drug Administration advisory panel has recommended against approving the fluoroquinolone gemifloxacin for treating acute ... $4.95 - Internal Medicine News - ECNext New Data Illustrate Geographic Variance in Rates of Drug Resistant … - Apr 5, 2005 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... RedOrbit Oscient Pharmaceuticals Completes Enrollment in Pivotal Phase III … - Mar 9, 2005 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... RedOrbit Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in … - Aug 22, 2006 FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic approved in the US for the ... Gemifloxacin is contraindicated in patients with a history of ... businesswire.com Full Results Released From Phase III Trial Comparing Five-Day and … - Sep 18, 2005 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... RedOrbit Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in … - Mar 2, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved in the US for the five-day treatment of acute bacterial exacerbations of chronic ... Genetic Engineering News - Genetic Engineering News (press release) FDA Accepts As ``Complete Response'' Oscient Pharmaceuticals' … - Nov 27, 2006 FACTIVE® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of ... Gemifloxacin is contraindicated in patients with a history of ... RedOrbit Regulatory Filing for FACTIVE Tablets Submitted in Europe - May 7, 2008 In clinical trials, drug-related rash was reported in 2.7% of patients receiving gemifloxacin and was more commonly observed in patients less than 40 years ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals Provides Preliminary Revenue Results for... - Apr 16, 2008 The Company reiterates its previously announced guidance of $96-$103 million in revenues from ANTARA and FACTIVE(R) (gemifloxacin mesylate) tablets in 2008 ... Genetic Engineering News - Genetic Engineering News (press release) Gemifloxacin.(Selected literature)(Brief article) - Sep 1, 2007 Ferguson BJ, Anon J, Poole MD, Hendrick K, Gilson M, Seltzer EG; Gemifloxacin 186 Study Group. Short treatment durations for acute bacterial rhinosinusitis: ... $4.95 - Formulary - ECNext gemifloxacin Oscient clinical data. - Oct 17, 2005 On 7 October 2005 Oscient reported data from two retrospective analysis studies of gemifloxacin (FACTIVE), a fluoroquinolone antibiotic that inhibits DNA ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Five-Day Therapy Course With Gemifloxacin Effective Against Community... - Oct 16, 2006 By Ed Susman. TORONTO, CANADA -- October 16, 2006 -- Five days of treatment with gemifloxacin is as effective as the standard 7-day treatment in treating ... DG News Oscient Pharmaceuticals Provides Preliminary Revenue Results for the ... - Jul 13, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Gemifloxacin for inpatient CAP found cost effective.(Infectious... - Dec 15, 2005 Gemifloxacin for inpatient CAP found cost effective.(Infectious Diseases)(community-acquired pneumonia) ... find Internal Medicine News articles. Pay-Per-View - Internal Medicine News - HighBeam Research Oscient Pharmaceuticals Announces Meeting Date for FDA Advisory … - Jun 28, 2006 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... Genetic Engineering News - Genetic Engineering News (press release) Webcast Alert: Oscient Pharmaceuticals to Present at the 9th Annual … - Nov 8, 2007 FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... businesswire.com Oscient Pharmaceuticals to Present at 25th Annual JPMorgan Healthcare... - Jan 11, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals' FACTIVE Tablets Subject of Poster … - Apr 4, 2006 The second presentation, titled "Dual Action of Gemifloxacin in Acute Bacterial Sinusitis ... Gemifloxacin is contraindicated in patients with a history of ... RedOrbit Press Release: Oscient Pharmaceuticals Provides Financial Projections... - Jan 1, 2007 FACTIVE® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... FierceBiotech Oscient Pharmaceuticals' Board of Directors Names 25-Year Lilly... - Jan 10, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Free with registration - Business Wire - AccessMyLibrary.com Gemifloxacin mesylate available.(Products)(drug for chronic bronchitis... - Jan 1, 2005 Factive (gemifloxacin mesylate) is available for the treatment of acute bacterial exacerbations of chronic bronchitis and mild to moderate ... Pay-Per-View - Family Practice News - Factiva, from Dow Jones Article: FDA panel rejects gemifloxacin for sinusitis.(Food and Drug ... - Oct 15, 2006 FDA panel rejects gemifloxacin for sinusitis.(Food and Drug Administration) ... find Family Practice News articles. GAITHERSBURG, MD. Pay-Per-View - Family Practice News - HighBeam Research Article: Gemifloxacin voted down for sinusitis.(News) - Internal... - Nov 1, 2006 Gemifloxacin voted down for sinusitis.(News) ... find Internal Medicine News articles. GAITHERSBURG, MD. -- A Food and Drug Administration advisory panel ... Pay-Per-View - Internal Medicine News - HighBeam Research Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of ... - Feb 28, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... businesswire.com gemifloxacin Oscient reports results of US FDA review meeting. - Sep 25, 2006 ...bacterial sinusitis (ABS). At the meeting, the panel voted ten to four that the data from non-inferiority clinical trials of gemifloxacin were not ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Oscient Pharmaceuticals completes Factive sales force expansion in... - Mar 18, 2005 The sales force is currently concentrating on the commercialisation of Factive (gemifloxacin mesylate) tablets. Oscient began selling Factive in Sep 2004 ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Oscient Pharmaceuticals Amends FACTIVE License Agreement with LG … - Dec 29, 2006 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com OSCIENT COMPLETES ENROLLMENT IN PHASE IV OF FACTIVE … - Mar 1, 2007 FACTIVE (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of ... Gemifloxacin is contraindicated in patients with a history of ... $4.95 - Biotech Business - ECNext New Data on FACTIVE(R) Tablets and Ramoplanin Presented at the 45th … - Dec 16, 2005 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... businesswire.com Oscient Pharmaceuticals Announces Results of FDA Advisory Committee … - Sep 13, 2006 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... RedOrbit New Treatment Guidelines for Community-Acquired Pneumonia Highlight … - Feb 22, 2007 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... $4.95 - Business Wire - ECNext Clinical Data on FACTIVE(R) Tablets to be Presented at the 43rd... - Oct 7, 2005 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... businesswire.com Oscient Pharmaceuticals Provides Preliminary Revenue Results for... - Oct 11, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Genetic Engineering News - Genetic Engineering News (press release) Regulatory Filing For FACTIVE Tablets Submitted In Europe - May 9, 2008 In clinical studies with gemifloxacin, CNS effects have been reported infrequently. As with other fluoroquinolones, FACTIVE should be used with caution in ... Medical News Today - Medical News Today (press release) Oscient Pharmaceuticals Completes Sales Force Expansion; Company … - Oct 3, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals to Present at 24th Annual JPMorgan Healthcare... - Jan 9, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Oscient Pharmaceuticals Reports Financial Results for Fourth Quarter ... - Mar 6, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic b. Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at Roth Capital Partners 18th... - Feb 21, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Webcast Alert: Oscient Pharmaceuticals to Present at BIO CEO &... - Feb 9, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit FACTIVE(R) Tablets Subject of Five Presentations at Third Internationa... - Oct 9, 2006 ..."In our in vitro analyses, gemifloxacin appeared to be less likely to contribute to the ... Gemifloxacin is contraindicated in patients with a history of ... Free with registration - Business Wire - AccessMyLibrary.com Data on FACTIVE(R) Tablets Short-Course Therapy in Patients with Co- … - Oct 13, 2006 In a poster focused on short-course gemifloxacin therapy in CAP patients with certain ... Gemifloxacin was generally well-tolerated with a low incidence of ... Free with registration - Business Wire - AccessMyLibrary.com Clinical Data on FACTIVE(R) Tablets to Be Presented at the 43rd... - Sep 30, 2005 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... RedOrbit í€´ë†€ë¡ ê³„ í•ê· ì œ, â€œì•„í‚¬ë ˆìŠ¤ê±´ 파열 조심â€? 블랙박스 ê²½ê³ - Jul 10, 2008 ...주로 ì•„í‚¬ë ˆìŠ¤ ê±´ 파열ì?´ë©° ì?´ëŸ¬í•œ ê²½ê³ ì¡°ì¹˜ë¥¼ 취한 약물ì?€ ciprofloxacin(Cipro, Cipro XR ë°? Proquin XR 등), gemifloxacin(Factive), levofloxacin(Levaquin), ... 메디í?¬ë‰´ìŠ¤ Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of ... - Apr 20, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... Genetic Engineering News - Genetic Engineering News (press release) FDA advisers meet on Factive's rash risks.(Tuesday, Sept. 12) - Sep 18, 2006 The FDA on Monday publicized side-effect concerns around Factive (gemifloxacin mesylate), Oscient Pharmaceuticals Corp.'s drug that is being reviewed by an ... Free with registration - BioWorld Week - AccessMyLibrary.com Oscient Pharmaceuticals Achieves Primary Endpoint in Phase III Trial... - Jun 6, 2005 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... RedOrbit FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five- … - May 2, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic ... In clinical studies with gemifloxacin, CNS effects have been reported infrequently. ... Free with registration - Business Wire - AccessMyLibrary.com Pneumonia Medications - Pneumonia Health Information - NY Times … - Apr 14, 2008 However, they should be given a fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin) or a beta-lactam (preferably high-dose amoxicillin or ... New York Times Oscient Pharmaceuticals Receives Approvable Letter from FDA for … - Sep 22, 2006 Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product ... Genetic Engineering News - Genetic Engineering News (press release) Shorter treatment duration may be better for pneumonia.(Infectious … - Dec 15, 2005 MONTREAL -- Short-course therapy with oral gemifloxacin is effective for the treatment ... To compare the efficacy of 5-day gemifloxacin treatment with the ... Free with registration - Internal Medicine News - AccessMyLibrary.com Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae... - Jun 1, 2005 First-step transformants were generated by the introduction of a parC or gyrA fragment, and these were selected on 0.06 [micro]g/mL gemifloxacin (SmithKline ... $4.95 - Emerging Infectious Diseases - ECNext A Year in Review and Looking Ahead: New Pharmaceutical Treatment … - Dec 8, 2005 Gemifloxacin mesylate, which is given daily (320 mg for 5 to 7 days), ... Gemifloxacin is contraindicated in patients with a history of hypersensitivity to ... Medscape Medication options for the treatment of CAP.(Letters to the Editor)( … - Nov 1, 2006 Gemifloxacin (Factive) is a newly released oral fluoroquinolone that is the most potent in vitro ... Efficacy and safety of gemifloxacin in the treatment of ... Free with registration - American Family Physician - AccessMyLibrary.com Shorter treatment duration may be better for pneumonia.(Infectious … - Dec 15, 2005 ...find Internal Medicine News articles. MONTREAL -- Short-course therapy with oral gemifloxacin is effective for the treatment of mild to moderate co... Pay-Per-View - Internal Medicine News - HighBeam Research Medication options for the treatment of CAP.(Letters to the Editor)( … - Nov 1, 2006 Gemifloxacin (Factive) is a newly released oral fluoroquinolone that is the most potent in vitro ... Efficacy and safety of gemifloxacin in the treatment of ... $4.95 - American Family Physician - ECNext Article: Antibiotics, topical steroids show no effect in acute... - Jan 1, 2008 Article: FDA panel rejects gemifloxacin for sinusitis.(Food and Drug ... Family Practice News; October 15, 2006 ; 700+ words ... ... the fluoroquinolone ... Pay-Per-View - Family Practice News - HighBeam Research Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of … - Jan 26, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Bloomberg Printer-Friendly Page - Nov 2, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Bloomberg Oscient Pharmaceuticals Reports Third Quarter 2008 Financial Results - Nov 4, 2008 Revenues from the antibiotic FACTIVE ® (gemifloxacin mesylate) tablets totaled $3.7 million in the third quarter of 2008, compared to $2.8 million in the ... International Business Times Oscient Pharmaceuticals Reports Second Quarter 2008 Financial Results - Aug 1, 2008 ...$18.4 million in revenue from the cardiovascular drug ANTARA and $1.9 million in revenue from the antibiotic FACTIVE(R) (gemifloxacin mesylate) tablets. ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Participate in the Rodman & Renshaw 10th … - Nov 5, 2008 ...of the Company; highlight details on the recent market performance of ANTARA ® (fenofibrate) capsules and FACTIVE ® (gemifloxacin mesylate) tablets; ... International Business Times FinancialContent.com - Stock Quotes and Business News - Aug 12, 2008 ...highlight details on the recent market performance of ANTARA®(fenofibrate) capsules and FACTIVE® (gemifloxacin mesylate) tablets; and discuss the ... cbs5.com Publicis Selling Solutions (PSS) launched Oscient Pharmaceuticals'... - Jan 1, 2005 Publicis Selling Solutions (PSS) launched Oscient Pharmaceuticals' first sales force in support of its flagship antibiotic, Factive (gemifloxacin). ... $9.94 - Pharmaceutical Executive - Alacra Store Oscient Pharmaceuticals Provides Preliminary Revenue Results for the ... - Oct 10, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) FDA Mandates Black Box Warning for Some Antibiotics - Jul 8, 2008 ...ciprofloxacin extended release (marketed as Cipro XR and Proquin XR); gemifloxacin (marketed as Factive); levofloxacin (marketed as Levaquin); ... Washington Post Use fluoroquinolones selectively in pneumonia: incorrect dosing and … - Nov 1, 2005 The approved agents, including gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin, ... Article: Gemifloxacin for inpatient CAP found cost effective. ... Pay-Per-View - Internal Medicine News - HighBeam Research Oscient Pharmaceuticals Provides Preliminary Revenue Results for the ... - Apr 11, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Press Release: Menarini Group - SWOT Analysis. - M2 Presswire | … - Sep 30, 2008 Business Wire; January 4, 2007 ; 700+ words ... ... gemifloxacin mesylate) tablets in Europe to Menarini Group, a leading European pharmaceutical ... early ... Pay-Per-View - M2 Presswire - HighBeam Research OSCIENT EXPECTS TOTAL REVENUES OF $23 MILLION FOR Q1 2007. … - May 1, 2007 FACTIVE (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... $4.95 - Biotech Financial Reports - ECNext Oscient Pharmaceuticals Completes Acquisition of Cardiovascular … - Aug 21, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Oscient Pharmaceuticals and Pfizer, SA de CV Announce Approval of … - Aug 1, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Genetic Engineering News - Genetic Engineering News (press release) Press Release: Menarini Group - SWOT Analysis. - M2 Presswire | … - Aug 28, 2008 Business Wire; January 4, 2007 ; 700+ words ... ... gemifloxacin mesylate) tablets in Europe to Menarini Group, a leading European pharmaceutical ... early ... Pay-Per-View - M2 Presswire - HighBeam Research Oscient Pharmaceuticals Agrees to Acquire Cardiovascular Therapy … - Jul 24, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at Roth Capital Partners New York ... - Aug 31, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Oscient Pharmaceuticals Reports Financial Results for Second Quarter ... - Aug 2, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at Rodman & Renshaw 8th Annual … - Oct 30, 2006 The Company markets two products: FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Present at Rodman & Renshaw 8th Annual … - Nov 6, 2006 The Company markets two products: FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of ... businesswire.com Oscient Pharmaceuticals to Present at CE Unterberg, Towbin Emerging … - Oct 26, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare … - Sep 9, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... businesswire.com Oscient Pharmaceuticals Reports Financial Results for Third Quarter … - Oct 31, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals and Abbott Canada Enter into … - Aug 10, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Oscient Pharmaceuticals and Menarini Group Enter into European … - Jan 4, 2007 FACTIVE (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - M2 Presswire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at Fourth Annual JMP Securities … - Mar 2, 2005 The Company is marketing FACTIVE (R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... businesswire.com July Issue of Journal of Antimicrobial Chemotherapy Highlights Study... - Jun 12, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and. Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals Provides Financial Projections for Fiscal... - Dec 8, 2006 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Present at Fourth Annual JMP Securities … - Feb 23, 2005 The Company is marketing FACTIVE (R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Participate in the Sixth Annual JMP... - May 15, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) CORRECTED: Webcast Alert: Oscient Pharmaceuticals to Present at … - Mar 8, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Present at Fifth Annual JMP Securities … - Mar 2, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at the JMP Securities Sector Focus... - Nov 13, 2006 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare … - Sep 6, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... businesswire.com Oscient Pharmaceuticals Reports Financial Results for First Quarter... - Mar 31, 2007 FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... businesswire.com Oscient Pharmaceuticals to Present at Fifth Annual JMP Securities … - Mar 9, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Oscient Pharmaceuticals to Present at the JMP Securities Sector Focus... - Nov 16, 2006 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... businesswire.com Oscient Pharmaceuticals to Present at 25th Annual JPMorgan Healthcare... - Dec 19, 2006 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at First Albany Capital Annual... - Dec 6, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Brand Names/Synonyms: Gemifloxacin is also known by the following brand names and/or synonymsFactive; Gemifloxacin; Gemifloxacin Mesilate; Gemifloxacin [Inn] Drug Category: Gemifloxacin is categorized under the following by the FDA: Anti-bacterial Agents; ATC:J01MA15 Dosage Forms: TABLET Absorption: Gemifloxacin is rapidly absorbed from the gastrointestinal tract. The absolute bioavailability of the 320 mg tablet averaged approximately 71% (95% CI 60%-84%). Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 1-acetyloxycyclohexane-1-carboxylicacid |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |